{
  "metformin": [
    {
      "id": "doc_met_1",
      "title": "Metformin Strategic Roadmap 2025",
      "type": "strategy_deck",
      "year": 2024,
      "key_takeaways": [
        "Focus on emerging markets where diabetes prevalence is rising",
        "Explore fixed-dose combinations with SGLT2 inhibitors",
        "Defend market share against generic erosion"
      ],
      "comparative_table": [],
      "pdf_url": "#"
    },
    {
      "id": "doc_met_2",
      "title": "Field Insights: Metformin Adoption in NAFLD",
      "type": "field_report",
      "year": 2024,
      "key_takeaways": [
        "HCPs are prescribing off-label for pre-diabetes and NAFLD",
        "Patient adherence issues due to gastrointestinal side effects",
        "Request for sustained release formulations in lower doses"
      ],
      "comparative_table": [],
      "pdf_url": "#"
    },
    {
      "id": "doc_met_3",
      "title": "Metformin Clinical Summary (NAFLD)",
      "type": "clinical_summary",
      "year": 2023,
      "key_takeaways": [
        "Modest weight loss observed in non-diabetic obese patients",
        "Liver enzyme improvement in 40% of subjects",
        "No safety signals in long-term usage"
      ],
      "comparative_table": [],
      "pdf_url": "#"
    }
  ],
  "keytruda": [
    {
      "id": "doc_key_1",
      "title": "Keytruda Lifecycle Management Strategy",
      "type": "strategy_deck",
      "year": 2024,
      "key_takeaways": [
        "Prioritize adjuvant indications in early-stage cancers",
        "Develop subcutaneous formulation to extend patent life",
        "Combination strategy with novel TIGIT inhibitors"
      ],
      "pdf_url": "#"
    },
    {
      "id": "doc_key_2",
      "title": "Competitor Analysis: PD-1/L1 Landscape",
      "type": "intelligence_report",
      "year": 2024,
      "key_takeaways": [
        "Opdivo losing share in 1L NSCLC",
        "Tecentriq aggressive in SCLC",
        "BeiGene pricing pressure in China market"
      ],
      "pdf_url": "#"
    }
  ],
  "humira": [
    {
      "id": "doc_hum_1",
      "title": "Humira Biosimilar Defense Plan",
      "type": "strategy_deck",
      "year": 2023,
      "key_takeaways": [
        "Maximize conversion to High Concentration formulation",
        "Payer contracting strategies to maintain formulary status",
        "Volume share erosion expected to be 20-30% in Year 1"
      ],
      "pdf_url": "#"
    },
    {
      "id": "doc_hum_2",
      "title": "Sales Force Feedback Q4 2023",
      "type": "field_report",
      "year": 2023,
      "key_takeaways": [
        "Dermatologists stickier to brand than Rheumatologists",
        "Patients prefer the citrate-free injection experience"
      ],
      "pdf_url": "#"
    }
  ]
}